Obexelimab for the Treatment of IgG4-Related Disease.
N Engl J MedJun 2, 2026 (epub)
Emanuel Della-Torre, Matthew C Baker, Wen Zhang et al.
✦ AI-curated · Sources linked
In 30 seconds
This phase 3 randomized controlled trial evaluated obexelimab in 194 patients with active IgG4-related disease. The study found that obexelimab significantly prolonged the time to the first disease flare requiring rescue therapy compared to placebo (hazard ratio, 0.44; P<0.001). Additionally, it demonstrated improved rates of complete remission and reduced glucocorticoid use.
Key findings
- Obexelimab significantly increased time to first disease flare (hazard ratio, 0.44; P<0.001).
- Complete remission rates were higher with obexelimab (37.1%) compared to placebo (19.6%, P = 0.005).
- Cumulative glucocorticoid rescue therapy was lower in the obexelimab group (329.5 mg) than in the placebo group (929.8 mg, P = 0.004).
Why it matters
The findings suggest that obexelimab may offer a safer and more effective alternative to glucocorticoids for managing IgG4-related disease, potentially reducing relapse rates and glucocorticoid-related side effects.